| 2.32 0.09 (4.04%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.79 | 1-year : | 4.68 |
| Resists | First : | 3.24 | Second : | 4.01 |
| Pivot price | 2.37  |
|||
| Supports | First : | 2.01 | Second : | 1.68 |
| MAs | MA(5) : | 2.22 |
MA(20) : | 2.44 |
| MA(100) : | 2.91 |
MA(250) : | 3.97 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 16.3 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 10.27 | Low : | 2.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XTLB ] has closed above bottom band by 40.0%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.38 - 2.4 | 2.4 - 2.41 |
| Low: | 2.21 - 2.22 | 2.22 - 2.24 |
| Close: | 2.3 - 2.32 | 2.32 - 2.34 |
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Sat, 23 May 2026
XTL Announces Receipt of Staff Delist Determination from Nasdaq - The Manila Times
Fri, 22 May 2026
Missed SEC filing puts XTL’s Nasdaq trading status at risk - Stock Titan
Fri, 22 May 2026
Nasdaq warns XTL Biopharmaceuticals (NASDAQ: XTLB) on late 20-F and listing defects - Stock Titan
Sat, 16 May 2026
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise - The Globe and Mail
Wed, 29 Apr 2026
XTLB Stock Holds Tight As Traders Watch Biotech Penny Setup - timothysykes.com
Wed, 29 Apr 2026
XTLB Stock Spikes On Volume As Traders Eye Breakout - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 275 (M) |
| Held by Insiders | 38.4 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -3.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 0 % |
| Operating Margin | -853.6 % |
| Return on Assets (ttm) | -240.6 % |
| Return on Equity (ttm) | -577.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.95 |
| Sales Per Share | 0.4 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | 2.2 |
| Price to Book value | 0 |
| Price to Sales | 5.68 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|